Anlon Healthcare LTD IPO 2025

Introduction Anlon Healthcare LTD IPO 2025

• Company Name : Anlon Healthcare LTD.
• Symbol : ANLON.
• Promoters : Mr. Punitkumar R. Rasadia, Mamata Rasadia (more than 20 years in pharma sector).
• Industry : Pharmaceuticals & Healthcare.
• Products : Active Pharmaceutical Ingredients (APIs) and Intermediates.
• Established : 2009.
• Total IPO size : ₹121.03 Crores.

Important Dates

• Open : Aug 26, 2025.
• Close : Aug 29, 2025.
• Allotment : Sept 1, 2025 (Tentative).
• Listing : Sept 3, 2025 (BSE & NSE).
• Price Band : ₹86 to ₹91 per Equity Share.
• Face Value : ₹10 per share.
• Lot Size : 164 shares (≈ ₹14,900 at upper band).
• Registrar : KARVY.

Important Documents

• Click here for audit/annual reports.
• Click here for financial reports.

Key Business Highlights

• Manufacturer of high-purity APIs and intermediates.
• 65+ commercial products, 28 in pilot scale, and 49 in lab testing.
• Key product: Loxoprofen Sodium Dihydrate (used in pain relief and arthritis).
• Global presence – DMFs filed in EU, Japan, Russia, South Korea; applying for US FDA.
• Strong R&D pipeline.
• IPO funds to be used for capacity expansion, working capital, debt repayment.

Industry Overview

• Indian pharma industry is valued at USD 50 billion+.
• APIs and intermediates form a large part of global healthcare supply chains.
• Rising demand due to generic drugs and affordable healthcare needs.
• Government push under PLI scheme for pharma.
• Increasing outsourcing by global pharma giants.

Journey

• Started in 2009 in Rajkot, Gujarat.
• Built a strong foundation in pharma intermediates.
• Expanded capacity with modern facilities.
• Received global approvals and entered multiple regulated markets.
• Today, Anlon Healthcare IPO is seen as a step to grow globally.

Financial state

• Revenue Growth : ₹66 Cr (FY24) → ₹120 Cr (FY25).
• Net Profit : ₹9.7 Cr (FY24) → ₹20.5 Cr (FY25).
• EBITDA Margin : Improved with scale.
• P/E Valuation : ~19x.
• EV/EBITDA : ~16.7x.

Risk

• Heavy reliance on single manufacturing unit.
• High competition in the API and generic market.
• Any delay in US FDA approval may impact growth.
• Valuation considered expensive by some analysts.
• Sensitive to changes in raw material prices.

Conclusion

• Anlon Healthcare IPO 2025 has strong fundamentals and global opportunities.
• Steady financial growth with improving profitability.
• Risks include valuation and dependency on one plant.
• Analysts are mixed: Some suggest long-term subscribe, while others recommend caution.
• Suitable for investors with long-term horizon in the healthcare sector.

Disclaimer – This is not an investment advice. It is for educational and informational purposes only. Stock discussed in this article is used for as example. Please read our disclaimer for more.